Best Peptides for Weight Loss & Fat Loss in 2026: Cost & Evidence

Important: This article reviews research on peptides studied for weight and fat loss. It is not medical advice, and the trial figures below are study outcomes, not dosing recommendations. Several of these compounds are not approved by the FDA for any use and are sold for laboratory research purposes only. Consult a licensed healthcare professional before using any compound for weight management.

"Peptides for fat loss" has become one of the most searched health topics of 2026 — but the term lumps together compounds with wildly different evidence. Some have large, peer-reviewed human trials behind them. Others failed in humans despite promising mouse data. This guide ranks the most-discussed options by what the research actually shows, then gives you honest cost-per-mg and where to buy.

How we ranked these peptides#

We weighted three things: strength of human evidence (peer-reviewed trials beat anecdotes), magnitude of fat/weight loss reported, and safety profile. We separate compounds that are FDA-approved as branded drugs (and also sold as research-grade peptides) from those that are purely investigational or research-use-only. Where a compound underperformed in humans, we say so — affiliate interest never overrides the data.

Quick comparison: weight-loss peptides at a glance#

GLP-1 and multi-agonist peptides (strongest for weight loss)#

These incretin-based compounds have the largest, best-documented effects — and they're where the real demand sits.

Tirzepatide — the proven heavyweight#

Tirzepatide is a dual agonist that activates both GLP-1 and GIP receptors, blunting appetite and slowing gastric emptying. In the 72-week SURMOUNT-1 trial, the 15 mg dose produced a mean body-weight reduction around 20.9%, with 43% of participants losing at least 15% of their weight (Jastreboff et al., NEJM 2022). It's FDA-approved as Mounjaro and Zepbound, which makes it the most validated option on this list. For the full breakdown, see our tirzepatide complete guide.

Retatrutide — the strongest emerging option#

Retatrutide adds a third target — the glucagon receptor — on top of GLP-1 and GIP. In its Phase 2 trial, the 12 mg dose drove a mean weight reduction of about 24.2% at 48 weeks, the largest figure yet reported for an incretin compound (Jastreboff et al., NEJM 2023). It is still investigational (not FDA-approved), which is exactly why it dominates the research-peptide market. See how it stacks up in our retatrutide vs tirzepatide comparison.

Semaglutide — the most available and studied#

Semaglutide is the single-agonist GLP-1 that started the category. In the 68-week STEP 1 trial, semaglutide 2.4 mg produced a mean weight loss of 14.9%, with most participants losing at least 5% (Wilding et al., NEJM 2021). It's FDA-approved as Ozempic and Wegovy and has the deepest long-term safety record of the three.

Cagrilintide — the amylin angle#

Cagrilintide works through a different pathway — it's a long-acting amylin analog that promotes satiety. On its own it produces roughly 10% weight loss, but the real interest is the combination with semaglutide ("CagriSema"), which has shown additive benefit in Phase 2 work (Frias et al., Lancet 2023). It's investigational and most often researched as a stacking compound.

Growth-hormone and fat-mobilizing peptides#

This tier is far weaker than the GLP-1s, and honesty matters here — the marketing often outruns the evidence.

AOD-9604 — popular, but it failed in humans#

AOD-9604 is a fragment of human growth hormone marketed for "targeted fat burning." The mouse data looked good; the human data did not. Development was halted after AOD-9604 failed to produce significant weight loss versus placebo in a 24-week trial of 536 subjects (anti-obesity pharmacotherapy review, PMC). It's researched today mostly for localized/joint applications — not as a serious weight-loss agent.

MOTS-c — promising mechanism, animal-only evidence#

MOTS-c is a mitochondrial-derived peptide that activates AMPK and behaves like an "exercise mimetic." In mice it prevents diet-induced obesity and improves insulin sensitivity (Lee et al., 2015). There are no controlled human weight-loss trials yet, so treat it as an early metabolic-research compound rather than a proven fat-loss tool.

Tesofensine — strong data, but not a peptide#

Tesofensine is technically a small-molecule triple monoamine-reuptake inhibitor, not a peptide — but it shows up constantly in these searches, so it's worth the honest note. In a 24-week Phase 2 trial, the 0.5 mg dose produced roughly 12.8 kg of weight loss versus 2 kg on placebo, with increased heart rate as the main concern (Astrup et al., Lancet 2008). It remains investigational.

Tirzepatide vs semaglutide vs retatrutide: which is strongest?#

By trial magnitude alone the order is clear: retatrutide (~24%) > tirzepatide (~21%) > semaglutide (~15%). But "strongest" isn't the whole story — semaglutide has the longest safety record and is the most available, tirzepatide is the strongest approved option, and retatrutide is still investigational. For research purposes, retatrutide and tirzepatide draw the most interest; our retatrutide vs tirzepatide breakdown compares them head-to-head on mechanism, dosing, and cost.

How to dose and reconstitute weight-loss peptides#

Research-grade peptides ship as a lyophilized powder that must be reconstituted with bacteriostatic water before measuring. Getting the concentration right is what determines how many syringe units equal your target dose. Use our reconstitution calculator to convert a target dose into exact units, and see the step-by-step reconstitution guide for the full method. Remember: the doses in this article are trial figures, not protocols.

Where to buy weight-loss peptides (price comparison)#

The catch with the GLP-1s is cost and sourcing. Branded Wegovy/Zepbound run well over $1,000/month through pharmacies; research-grade peptides are sold far cheaper but strictly for laboratory research use (not for human consumption). We track live vendor pricing so you can compare cost per mg across vetted suppliers — Peptide Supply Co. is our top-rated source.

GLP-1 & multi-agonist live pricing:

Fat-mobilizing compounds:

For full vendor reviews and COA details, see where to buy tirzepatide and where to buy retatrutide.

Safety, side effects and legal status#

The GLP-1 class shares a gastrointestinal side-effect profile — nausea, vomiting, and diarrhea are common, especially during dose escalation; in STEP 1 these were markedly more frequent than placebo (Wilding et al., NEJM 2021). Retatrutide's glucagon activity can raise heart rate, and tesofensine carries cardiovascular/stimulant cautions. Only semaglutide and tirzepatide are FDA-approved (as branded drugs); the rest are investigational or research-use-only and have not been approved for weight loss. None of this is medical advice — research compounds should be handled under appropriate professional and regulatory frameworks.

Frequently asked questions